chartexchange

Connect Biopharma Advances Rademikibart Toward Phase 3 In COPD

RTTNews | Sep 30, 2026 7:27 AM EDT


(RTTNews) - Wednesday, Connect Biopharma Holdings (CNTB) reported positive topline results from a global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation.

Read original article